JAK2 V617F mutation and 46/1 haplotype in Chinese Budd‐Chiari syndrome patients

Abstract

Our study showed that the presence of 46/1 haplotype increased the risk of JAK2V617F-positive BCS in China. In addition, low prevalence of JAK2V617F mutation in BCS patients suggested that myeloproliferative neoplasms (MPNs) should not be an etiological factor of BCS in China.

Thrombotic risk factors in Chinese nonmalignant and noncirrhotic patients with portal vein thrombosis

“…Previous studies have demonstrated that the distribution of thrombotic risk factors for Budd-Chiari syndrome was widely different between China and Western countries [14,[17][18][19]. This phenomenon could be extrapolated to nonmalignant and noncirrhotic patients with PVT because of the etiological similarity between PVT and Budd-Chiari syndrome.…”

Budd-Chiari syndrome and liver transplantation

“…Recently, a particular somatic mutation (V617F) in the Janus tyrosine kinase-2 (JAK2) gene in myeloid cells was identified in a study of chronic MPD (14). This mutation has been detected in around 40% of patients with primary BCS (15)(16)(17). Other causes of BCS such as Behcet's disease (18,19), antiphospholipid syndrome (20), and oral contraceptives (21) have been reported.…”

Use of Accessory Hepatic Vein Intervention in the Treatment of Budd–Chiari Syndrome

“…Budd-Chiari syndrome (BCS) is a rare disorder consisting of hepatic venous outflow obstruction at any level of hepatic vein (HV) and/or inferior vena cava (IVC) resulting in portal hypertension [1][2][3]. Intervention treatment, including recanalization and transjugular intrahepatic portosystemic shunt (TIPS), has been widely used to treat BCS.…”